Fredun Pharmaceuticals Ltd vs Sanofi Consumer Healthcare India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Fredun Pharmaceuticals Ltd is ₹ 2464 as of 06 May 15:30 . The P/E Ratio of Fredun Pharmaceuticals Ltd is 16 as of March 2025 .The P/E Ratio of Sanofi Consumer Healthcare India Ltd is 0 as of March 2025 . The Market Cap of Fredun Pharmaceuticals Ltd is ₹ 315.67 crore as of March 2025 .The Market Cap of Sanofi Consumer Healthcare India Ltd is ₹ 0 crore as of March 2025 . The revenue of Fredun Pharmaceuticals Ltd for the Dec '25 is ₹ 160.92 crore as compare to the Sep '25 revenue of ₹ 145.29 crore. This represent the growth of 10.76% The revenue of Sanofi Consumer Healthcare India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Fredun Pharmaceuticals Ltd for the Dec '25 is ₹ 26.34 crore as compare to the Sep '25 ebitda of ₹ 22.33 crore. This represent the growth of 17.96% The ebitda of Sanofi Consumer Healthcare India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Fredun Pharmaceuticals Ltd changed from ₹ 13.74 crore to ₹ 10.48 crore over 5 quarters. This represents a CAGR of -19.48% The net profit of Sanofi Consumer Healthcare India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Fredun Pharmaceuticals Ltd changed from 13.9 % on March 2021 to 0 % on December 2024 . This represents a CAGR of -100.00% over 7 yearsThe Dividend Payout of Sanofi Consumer Healthcare India Ltd changed from 6.06 % on December 2023 to 69.89 % on December 2024 . This represents a CAGR of 239.60% over 2 years .

About Fredun Pharmaceuticals Ltd

Incorporated in 1987 as a private limited company, Fredun Pharmaceuticals Limited (FPL) was converted into a public limited company in Mar.'94.
The Company was promoted by Nariman Medhora and Daulat N Medhora.
The promoters initially established D N Pharma, a proprietary firm, for the manufacture and export of pharmaceutical formulations.
Since 1993, D N Pharma's operations were phased out in order to switch over the business to FPL. The Company is well diversified in the business ranging from Formulations to Diagnostics to Consultancy.
The Company has an unique range of products, from niche formulations , anti-diabetics to the latest antiretroviral and anti - Hypertensive products.

About Sanofi Consumer Healthcare India Ltd

Sanofi Consumer Healthcare India Limited was incorporated on May 10, 2023, as part of Sanofi's global strategy to establish a standalone Consumer Healthcare business.
This strategic move resulted in the demerger of the Consumer Healthcare business from Sanofi India Limited (SIL) into the Company through a Scheme of Arrangement, thereby creating a distinct legal entity.
The Scheme of Arrangement, which was sanctioned by the National Company Law Tribunal, Mumbai (NCLT) enabled the seamless transfer and vesting of all assets, liabilities, and operations of SIL to the Company. Pursuant to the Scheme becoming effective, the Consumer Healthcare Division (CHC) business of Sanofi India Limited (SIL) got demerged into the Company as a going concern through the Scheme of Arrangement and became effective from June 1, 2024.

FAQs for the comparison of Fredun Pharmaceuticals Ltd and Sanofi Consumer Healthcare India Ltd

Which company has a larger market capitalization, Fredun Pharmaceuticals Ltd or Sanofi Consumer Healthcare India Ltd?

Market cap of Fredun Pharmaceuticals Ltd is 1,358 Cr while Market cap of Sanofi Consumer Healthcare India Ltd is 10,728 Cr

What are the key factors driving the stock performance of Fredun Pharmaceuticals Ltd and Sanofi Consumer Healthcare India Ltd?

The stock performance of Fredun Pharmaceuticals Ltd and Sanofi Consumer Healthcare India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Fredun Pharmaceuticals Ltd and Sanofi Consumer Healthcare India Ltd?

As of May 6, 2026, the Fredun Pharmaceuticals Ltd stock price is INR ₹2464.55. On the other hand, Sanofi Consumer Healthcare India Ltd stock price is INR ₹4658.2.

How do dividend payouts of Fredun Pharmaceuticals Ltd and Sanofi Consumer Healthcare India Ltd compare?

To compare the dividend payouts of Fredun Pharmaceuticals Ltd and Sanofi Consumer Healthcare India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.